Indicators of amyloid burden in a population-based study of cognitively normal elderly

Michelle M. Mielke, Heather J. Wiste, Stephen D. Weigand, David S. Knopman, Val J. Lowe, Rosebud O. Roberts, Yonas E. Geda, Dana M. Swenson-Dravis, Bradley F. Boeve, Matthew L. Senjem, Prashanthi Vemuri, Ronald C. Petersen, Clifford R. Jack

Research output: Contribution to journalArticlepeer-review

110 Scopus citations


Objectives: Secondary prevention trials in subjects with preclinical Alzheimer disease may require documentation of brain amyloidosis. The identification of inexpensive and noninvasive screening variables that can identify individuals who have significant amyloid accumulation would reduce screening costs. Methods: A total of 483 cognitively normal (CN) individuals, aged 70-92 years, from the population-based Mayo Clinic Study of Aging, underwent Pittsburgh compound B (PiB)-PET imaging. Logistic regression determined whether age, sex, APOE genotype, family history, or cognitive performance was associated with odds of a PiB retention ratio

Original languageEnglish (US)
Pages (from-to)1570-1577
Number of pages8
Issue number15
StatePublished - Oct 9 2012
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)


Dive into the research topics of 'Indicators of amyloid burden in a population-based study of cognitively normal elderly'. Together they form a unique fingerprint.

Cite this